6 results on '"Sizova, N"'
Number of results to display per page
Search Results
2. [HIV infection in Saint Petersburg: the changing face of the epidemic].
- Author
-
Bogoiavlenskiĭ GV, Mebel' BD, Davydova AA, Makarenko GA, Akhtyrskaia NA, and Sizova NV
- Subjects
- Adolescent, Adult, Female, HIV Infections transmission, HIV Seroprevalence, Humans, Male, Middle Aged, Morbidity trends, Russia epidemiology, Substance-Related Disorders epidemiology, Disease Outbreaks statistics & numerical data, HIV Infections epidemiology, HIV-1, Urban Population statistics & numerical data
- Abstract
The specific features of the epidemiological situation in St. Petersburg at the first stage (1987-1995) and the second stage (1986-1999) of the development of HIV infection are described. During this period morbidity in HIV infection, starting from the insignificant rate of growth, sharply increased. For the first time injecting drug users were noted to come out to the foreground in the structure of the contingent of persons affected by HIV infection (57.5% and 72.6% in 1998 and 1999 respectively). Such change on the epidemic situation requires corrections in the strategy and tactics of preventive measures and medical assistance. To control HIV infection among drug users, only the combination of medical assistance given by narcologists with the realization of all elements of the program "Harm Reduction" can be effective.
- Published
- 2000
3. [The use of a method for the quantitative determination of HIV-1 RNA for assessing the severity and prognosis of the development of the disease].
- Author
-
Smol'skaia TT, Sizova NV, Korovina GI, Maslov VP, Kevlova NA, Novikova VA, and Bogoiavlenskiĭ GV
- Subjects
- Biomarkers blood, Disease Progression, HIV Infections diagnosis, Humans, Prognosis, Viral Load statistics & numerical data, HIV Infections blood, HIV-1 genetics, RNA, Viral blood, Severity of Illness Index, Viral Load methods
- Abstract
The informatory role of a new marker of HIV infection, characterizing the content of HIV-1 RNA in the biological fluids of the patient's body, is evaluated. The quantitative determination of HIV-1 RNA, carried out in a single assay, was made in the blood of 25 HIV-infected patients. These studies confirmed that the determination of the level of RNA in the plasma (viral load) was a reliable criterion indicating the severity and progress of the disease. The viral load of more than 100,000 copies/ml was a sign prognosticating the future pronounced progress of the disease in spite of moderate clinical manifestations and relatively high values of CD4 cells in the patient's blood at the moment of testing.
- Published
- 1999
4. [HIV-infection in St. Petersburg].
- Author
-
Rakhmanova AG, Prigozhina VK, Popova IA, Khaldeeva NA, Sizova NV, Giaurgieva OKh, Volkova GV, and Romanova EI
- Subjects
- Adolescent, Adult, Female, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Russia epidemiology, HIV Infections epidemiology
- Published
- 1998
5. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
- Author
-
Lathouwers, Erkki, Wong, Eric Y, Brown, Kimberley, Baugh, Bryan, Ghys, Anne, Jezorwski, John, Mohsine, El Ghazi, Van Landuyt, Erika, Opsomer, Magda, De Meyer, Sandra, De Wit, S, Florence, E, Vandekerckhove, L, Vandercam, B, Brunetta, J, Klein, M, Murphy, D, Rachlis, A, Walmsley, S, Ajana, F, Cotte, L, Girard, P-M, Katlama, C, Molina, J-M, Poizot-Martin, I, Raffi, F, Rey, D, Reynes, J, Teicher, E, Yazdanpanah, Y, Arasteh, K, Bickel, M, Bogner, J, Esser, S, Faetkenheuer, G, Jessen, H, Kern, W, Rockstroh, J, Spinner, C, Stellbrink, H-J, Stoehr, A, Antinori, A, Castelli, F, Chirianni, A, De Luca, A, Di Biagio, A, Galli, M, Lazzarin, A, Maggiolo, F, Maserati, R, Mussini, C, Garlicki, A, Gasiorowski, J, Halota, W, Horban, A, Parczewski, M, Piekarska, A, Belonosova, E, Chernova, O, Dushkina, N, Kulagin, V, Ryamova, E, Shuldyakov, A, Sizova, N, Tsybakova, O, Voronin, E, Yakovlev, A, Antela, A, Arribas, JR, Berenguer, J, Casado, J, Estrada, V, Galindo, MJ, Garcia Del Toro, M, Gatell, JM, Gorgolas, M, Gutierrez, F, Gutierrez, MDM, Negredo, E, Pineda, JA, Podzamczer, D, Portilla Sogorb, J, Rivero, A, Rubio, R, Viciana, P, De Los Santos, I, Clarke, A, Gazzard, BG, Johnson, MA, Orkin, C, Reeves, I, Waters, L, Benson, P, Bhatti, L, Bredeek, F, Crofoot, G, Cunningham, D, DeJesus, E, Eron, J, Felizarta, F, Franco, R, Gallant, J, Hagins, D, Henry, K, Jayaweera, D, Lucasti, C, Martorell, C, McDonald, C, McGowan, J, Mills, A, Morales-Ramirez, J, Prelutsky, D, Ramgopal, M, Rashbaum, B, Ruane, P, Slim, J, Wilkin, A, deVente, J, Moutschen, M, Van Wijngaerden, E, Vekerckhove, L, Vercam, B, Conway, B, Shafran, S, Janssen Pharmaceutica [Beerse], Janssen Pharmaceutical Research and Development Titusville, AMBER and EMERALD Study Groups: S De Wit, E Florence, L Vandekerckhove, B Vandercam, J Brunetta, M Klein, D Murphy, A Rachlis, S Walmsley, F Ajana, L Cotte, P-M Girard, C Katlama, J-M Molina, I Poizot-Martin, F Raffi, D Rey, J Reynes, E Teicher, Y Yazdanpanah, K Arastéh, M Bickel, J Bogner, S Esser, G Faetkenheuer, H Jessen, W Kern, J Rockstroh, C Spinner, H-J Stellbrink, A Stoehr, A Antinori, F Castelli, A Chirianni, A De Luca, A Di Biagio, M Galli, A Lazzarin, F Maggiolo, R Maserati, C Mussini, A Garlicki, J Gasiorowski, W Halota, A Horban, M Parczewski, A Piekarska, E Belonosova, O Chernova, N Dushkina, V Kulagin, E Ryamova, A Shuldyakov, N Sizova, O Tsybakova, E Voronin, A Yakovlev, A Antela, J R Arribas, J Berenguer, J Casado, V Estrada, M J Galindo, M Garcia Del Toro, J M Gatell, M Gorgolas, F Gutierrez, Mdm Gutierrez, E Negredo, J A Pineda, D Podzamczer, J Portilla Sogorb, A Rivero, R Rubio, P Viciana, I De Los Santos, A Clarke, B G Gazzard, M A Johnson, C Orkin, I Reeves, L Waters, P Benson, L Bhatti, F Bredeek, G Crofoot, D Cunningham, E DeJesus, J Eron, F Felizarta, R Franco, J Gallant, D Hagins, K Henry, D Jayaweera, C Lucasti, C Martorell, C McDonald, J McGowan, A Mills, J Morales-Ramirez, D Prelutsky, M Ramgopal, B Rashbaum, P Ruane, J Slim, A Wilkin, J deVente, S De Wit, E Florence, M Moutschen, E Van Wijngaerden, L Vandekerckhove, B Vandercam, J Brunetta, B Conway, M Klein, D Murphy, A Rachlis, S Shafran, S Walmsley, F Ajana, L Cotte, P-M Girard, C Katlama, J-M Molina, I Poizot-Martin, F Raffi, D Rey, J Reynes, E Teicher, Y Yazdanpanah, J Gasiorowski, W Halota, A Horban, A Piekarska, A Witor, J R Arribas, I Perez-Valero, J Berenguer, J Casado, J M Gatell, F Gutierrez, M J Galindo, Mdm Gutierrez, J A Iribarren, H Knobel, E Negredo, J A Pineda, D Podzamczer, J Portilla Sogorb, F Pulido, C Ricart, A Rivero, I Santos Gil, A Blaxhult, L Flamholc, M Gisslèn, A Thalme, J Fehr, A Rauch, M Stoeckle, A Clarke, B G Gazzard, M A Johnson, C Orkin, F Post, A Ustianowski, L Waters, J Bailey, P Benson, L Bhatti, I Brar, U F Bredeek, C Brinson, G Crofoot, D Cunningham, E DeJesus, C Dietz, R Dretler, J Eron, F Felizarta, C Fichtenbaum, J Gallant, J Gathe, D Hagins, S Henn, K W Henry, G Huhn, M Jain, C Lucasti, C Martorell, C McDonald, A Mills, J Morales-Ramirez, K Mounzer, R Nahass, H Olivet, O Osiyemi, D Prelutsky, M Ramgopal, B Rashbaum, G Richmond, P Ruane, A Scarsella, A Scribner, P Shalit, D Shamblaw, J Slim, K Tashima, G Voskuhl, D Ward, A Wilkin, J de Vente, and Malbec, Odile
- Subjects
0301 basic medicine ,[SDV]Life Sciences [q-bio] ,efficacy ,Human immunodeficiency virus (HIV) ,HIV Infections ,darunavir ,medicine.disease_cause ,VIRALLY SUPPRESSED ADULTS ,PLUS LAMIVUDINE ,DOUBLE-BLIND ,0302 clinical medicine ,INFECTION ,Medicine and Health Sciences ,Emtricitabine ,030212 general & internal medicine ,Darunavir ,Emtricitabine tenofovir alafenamide ,Alanine ,Cobicistat ,Single tablet regimen ,virus diseases ,Viral Load ,OPEN-LABEL ,3. Good health ,[SDV] Life Sciences [q-bio] ,Drug Combinations ,Infectious Diseases ,NON-INFERIORITY ,INITIAL TREATMENT ,Reverse Transcriptase Inhibitors ,Life Sciences & Biomedicine ,Tablets ,medicine.drug ,Adult ,TENOFOVIR DISOPROXIL FUMARATE ,Anti-HIV Agents ,Darunavir/Cobicistat ,Immunology ,archived RAMs ,Tenofovir alafenamide ,Drug Administration Schedule ,single-tablet regimen ,resistance ,03 medical and health sciences ,deep sequencing ,Virology ,Drug Resistance, Viral ,medicine ,darunavir/cobicistat/emtricitabine/TAF ,Humans ,Clinical Trials/Clinical Studies ,Tenofovir ,emtricitabine ,DRUG-RESISTANCE ,Science & Technology ,TREATMENT-NAIVE PATIENTS ,business.industry ,Adenine ,cobicistat ,030104 developmental biology ,TAF ,HIV-1 ,business - Abstract
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance analyses are presented. Postbaseline samples for genotyping/phenotyping were analyzed from protocol-defined virologic failures (PDVFs) with viral load (VL) ≥400 copies/mL at failure/later time points. Post hoc analyses were deep sequencing in AMBER, and HIV-1 proviral DNA from baseline samples (VL
- Published
- 2019
6. Multicenter epidemiological study to describe prevalence of advanced stage disease among newly diagnosed HIV-infected patients in the Russian Federation.
- Author
-
Pronin, A, Orlova-Morozova, E, Kaminskiy, G, Sizova, N, Ryamova, E, Plotnikova, J, Sibill, K, Kozyrev, O, Ibragimova, L, Nagimova, F, Fedotov, D, Trinh, R, Van de Steen, O, Zachry, W, and Kruglova, A
- Subjects
INFECTIOUS disease transmission ,VIRUS diseases ,HIV-positive persons ,HIV infections ,AIDS diagnosis - Abstract
Purpose of the study The proportion of HIV-infected persons diagnosed in an advanced stage of HIV disease (ASH) varies by country from 15 to 30%. Data are lacking on the proportion of new cases diagnosed in this late stage in Russia. The aim of this study was to estimate the proportion of and further characterize patients with ASH among newly diagnosed HIV-1 infected persons in the Russian Federation. Methods This was a cross-sectional, multicenter, epidemiologic study. Adult HIV-1 patients that were newly diagnosed within 90 days and naïve to highly active antiretroviral therapy were included at twelve centers/regions (Moscow Region, St Petersburg, Leningrad Region, Ufa, Kazan, Ulyanovsk, Volgograd, Yekaterinburg, Kemerovo, Krasnoyarsk, Irkutsk and Vladivostok) of the Russian Federation. ASH was defined as a CD4+ cell count ≤200 cells/mm
3 . Pairwise, two-tailed comparisons were conducted with an unadjusted 5% significance level. For comparison variables between patients with ASH and all other patients, Pearson's chi-square test was used. Summary of results 4540 patients were included. The overall proportion of ASH was 16.3% (95% CI; 15.3%, 17.4%). The median plasma HIV-1 RNA was 4.48 (Q1, Q3; 3.81, 5.07) log10 copies/mL. The proportion of patients with CD4+ cell count by categories is presented in . ASH was associated with male sex (62.3%), 26-40 and >40 years age groups, rural place of residence (18.9%), only primary and/or basic school education (complete or not complete) (39.4%), unemployment (40.5%), intravenous drug user as mode of HIV-1 transmission (39.5%), patient with clinical signs of immunodeficiency or condition related to HIV/AIDS as reason for primary HIV-1 testing (35.2%), HBV (5.4%), HCV (44.0%) as partly shown in . Conclusions The overall prevalence of ASH was 16.3%. At least 9 factors associated with ASH were revealed. Knowledge of these factors is valuable for planning, prevention and post-diagnosis services for HIV-infected patients presenting with advance stage disease. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.